GPT and hyperphosphatemia: Grade ≥ 3 AEsCabozantinib + nivolumab: 75% (most common: hypertension [13%]; hyponatraemia [9%]; PPES [8%]; diarrhoea [7%]; increased lipase [6%]; hyperphosphataemia [6%]; increased ALT [5%])Sunitinib: 71% (most common: hypertension [13%]; PPES [8%]; hyponatraemia [6%])